Congenital Diaphragmatic Hernia

---

Overview

Definition

Congenital Diaphragmatic Hernia (CDH) is a developmental defect of the diaphragm resulting in the incomplete closure of the pleuroperitoneal canal, allowing abdominal viscera (intestines, stomach, liver, spleen) to herniate into the chest cavity. This leads to pulmonary hypoplasia and subsequent pulmonary hypertension, which are the primary determinants of morbidity and mortality.

Epidemiology

• Incidence: Approximately 1 in 2,500 to 1 in 4,000 live births.
• Laterality: Occurs predominantly on the left side (80–85%), known as a Bochdalek hernia. Right-sided CDH accounts for 10–15%. Anterior defects (Morgagni) are rare (~2%).
• Associated Anomalies: Found in 30–50% of cases, most commonly cardiac (e.g., Tetralogy of Fallot, ventricular septal defects), chromosomal abnormalities (e.g., Trisomy 18, 13, structural aberrations), and genitourinary defects.

Classification

Type	Description	Location	Prevalence
Bochdalek	Posterolateral defect; failure of pleuroperitoneal membrane fusion.	Posterior/lateral diaphragm (left > right)	80–90%
Morgagni	Anteromedial defect; failure of fusion of the sternal and costal diaphragmatic elements.	Anterior/retrosternal (usually right)	2–5%
Hiatal	Enlargement of the esophageal hiatus (less common as a primary CDH).	Midline	Rare

---

Pathophysiology

Mechanism

CDH development typically occurs between the 8th and 10th weeks of gestation. The herniation of abdominal organs into the thorax during this critical period directly interferes with the normal development of the fetal lung.

1. Pulmonary Hypoplasia: Compression inhibits branching and proliferation of the bronchial tree (affecting airway generation, usually stopping at 10–15 generations instead of 23), resulting in a reduced number of alveoli and smaller true lung volume. It affects both lungs, but the ipsilateral lung is more severely impacted.
2. Pulmonary Hypertension (PPHN): The smaller lungs have fewer pulmonary arterioles, and the muscular walls of these vessels are abnormally thickened (hypertrophy of the media). This structural abnormality leads to fixed, elevated pulmonary vascular resistance (PVR). Postnatally, factors like hypoxia and acidosis worsen PVR, leading to persistent pulmonary hypertension of the newborn (PPHN), causing right-to-left shunting through the patent foramen ovale (PFO) and patent ductus arteriosus (PDA).
3. Gastrointestinal Maldevelopment: The small intestine may be arrested in its rotation and fixation, leading to malrotation in up to 30–50% of cases.

Risk Factors

• Genetic Factors: Syndromic CDH (chromosomal anomalies like Trisomy 18) or inherited single-gene defects (e.g., FOG2, GATA4).
• Environmental/Teratogens: Potential associations include exposure to certain solvents, pesticide exposure, and maternal use of SSRIs (though evidence is inconclusive).
• Other: Maternal obesity and pre-existing diabetes mellitus.

Protective Factors

• Currently, no proven, clinically implemented preventative measures exist for CDH development. Prenatal diagnosis allows for specialized delivery and immediate neonatal management, improving survival.

---

Clinical Presentation

Signs and Symptoms

Cardinal Features (Postnatal)

• Respiratory Distress: Often presenting immediately or within the first few hours of life (tachypnea, grunting, retractions, cyanosis).
• Cyanosis: Due to pulmonary hypertension and R-L shunting.
• Scaphoid Abdomen: Concave appearance due to the absence of abdominal viscera.

Early Signs

• Asymmetrical chest movement.
• Failure to oxygenate despite high fraction of inspired oxygen ($FiO_2$).
• Shifted point of maximal cardiac impulse (PMI).

Advanced Signs

• Severe refractory hypoxemia and hypercapnia.
• Shock and cardiovascular collapse secondary to severe PPHN and compression of the mediastinum (mediastinal shift).

Atypical Presentations

• Delayed Presentation: Less severe defects or those with a herniated sac (pleural effusion or hydrothorax protecting the lung) may present later in infancy or childhood with recurrent respiratory infections, chronic cough, or gastrointestinal obstruction.
• Morgagni Hernia: Typically presents later in life, often incidentally, or with nonspecific symptoms like dyspepsia or chest pain.

Physical Examination

Area	Inspection	Palpation	Auscultation
Chest	Retractions, asymmetrical chest wall expansion.	Displacement of the point of maximal impulse (PMI) away from the affected side.	Absent or diminished breath sounds on the ipsilateral side. Occasionally, bowel sounds heard in the chest.
Abdomen	Scaphoid (sunken) appearance.	Non-distended, often soft.	Normal/slight decrease in bowel sounds.

---

Diagnostic Approach

History Taking (Postnatal)

Key Questions

• Onset of respiratory distress (immediate at birth vs. delayed).
• Prenatal history: Was CDH diagnosed prenatally? (Often detected on screening ultrasound).
• Associated symptoms: Poor feeding, vomiting (may suggest malrotation).
• Family history of CDH or other congenital anomalies.

Red Flags

• Requires immediate and aggressive stabilization:
  • Respiratory failure at birth requiring immediate intubation.
  • Refractory hypoxemia ($SaO_2$ < 85%) despite mechanical ventilation.
  • Hypotension or evidence of shock.

Laboratory Tests

First-Line

• Arterial Blood Gas (ABG): Assesses $\text{pH}$, $PaCO_2$, and $PaO_2$. Aim for permissive hypercapnia ($PaCO_2$ 50–65 mmHg) and pre-ductal $SaO_2$ 85–95%.
• Complete Blood Count (CBC) and Basic Metabolic Panel (BMP): Assess for signs of infection or electrolyte imbalance.

Confirmatory

• Fetal Karyotyping/Chromosomal Microarray (CMA): If prenatally diagnosed or if other congenital anomalies are present, to screen for syndromic CDH.

Monitoring

• Serial ABGs, Lactate: To track stability, ventilation adequacy, and perfusion.
• Brain Natriuretic Peptide (BNP)/N-terminal pro-BNP (NT-proBNP): Useful in monitoring ventricular strain and pulmonary hypertension severity.

Imaging

Recommended

1. Chest Radiograph (CXR): Diagnostic.
   • Shows loops of bowel and sometimes the stomach bubble in the hemithorax.
   • Identifies mediastinal shift to the contralateral side.
   • Confirms placement of nasogastric tube (NGT) and endotracheal tube (ETT).
2. Echocardiogram (ECHO): Critical.
   • Assesses the severity of pulmonary hypertension (velocity of tricuspid regurgitation, estimation of pulmonary artery pressure).
   • Evaluates cardiac function (e.g., ventricular function, degree of shunting through PDA/PFO).
   • Rules out structural heart defects.

Advanced

1. Fetal Ultrasound/MRI (Prenatal Diagnosis):
   • Fetal Ultrasound: Detects polyhydramnios, displacement of the heart, and abdominal contents in the chest.
   • Fetal MRI: Provides volumetric measurements of lung size.
     • Observed-to-Expected Lung-to-Head Ratio (O/E LHR): The strongest predictor of postnatal survival. $\text{O/E LHR} < 25\%$ is associated with severe disease.
2. CT Scan (Rarely needed): May be used for late-presenting or complex atypical cases.

---

Management

Management is complex, requiring a coordinated approach by a multidisciplinary team (Neonatologists, Pediatric Surgeons, Pulmonologists, Anesthesiologists).

Acute Management (The First Hours of Life)

Immediate

1. Avoid Bag-Mask Ventilation: Manual ventilation introduces gas into the gastrointestinal tract, causing further distension, worsening lung compression, and hemodynamic instability.
2. Endotracheal Intubation (ETT): Immediate intubation and mechanical ventilation should be performed for respiratory distress.
3. Nasogastric Tube (NGT/OGT): Placement of an orogastric tube and connection to low continuous suction to decompress the stomach and bowel (preventing further lung compression).

Stabilization (The "Permissive Strategy")

• Ventilation Strategy:
  • Use gentle, low-pressure ventilation to minimize barotrauma and volutrauma (avoiding pneumothorax).
  • Permissive Hypercapnia: Target $PaCO_2$ 50–65 mmHg, provided $\text{pH} > 7.25$.
  • Pre-ductal saturation $\text{target}: 85–95\%$ (acceptable even if post-ductal saturation is lower, focusing on cerebral oxygenation).
  • Peak Inspiratory Pressure (PIP): Keep PIP $\le 25 \text{ cmH}_2\text{O}$.
• Cardiovascular Support:
  • Maintain systemic blood pressure above pulmonary artery pressure to minimize R-L shunting.
  • Use volume expanders (e.g., normal saline 10–20 $\text{mL/kg}$) and inotropes/vasopressors (e.g., dopamine, milrinone).

Emergency

• Refractory Hypoxemia/PPHN:
  • Inhaled Nitric Oxide (iNO): Often initiated for severe pulmonary hypertension ($PaO_2/FiO_2$ ratio < 150) at 20 ppm. Note: iNO effectiveness is limited if severe pulmonary hypoplasia is present.
  • ECMO Consideration: If severe PPHN or respiratory failure continues despite optimal conventional and iNO therapy (PaO2/FiO2 < 60, Oxygenation Index $\text{OI} > 40$).

Chronic Management (Post-Stabilization and Surgical Repair)

Pharmacological

• Sedation/Analgesia: Necessary during mechanical ventilation (e.g., Fentanyl, Midazolam).
• Pulmonary Vasodilators: Post-repair, targeted therapy for PPHN may include oral pulmonary vasodilators:
  • Sildenafil: (PDE-5 inhibitor) 0.5–2.0 $\text{mg/kg}$ PO $\text{TID}$.
  • Bosentan (Endothelin receptor antagonist): Used for long-term management of chronic pulmonary hypertension.
• Antacids/Prokinetics: Proton pump inhibitors (PPIs) or H2 blockers, and prokinetics (e.g., Erythromycin) are often required for significant gastroesophageal reflux (GERD), which is very common post-repair.

Non-pharmacological

• Timing of Surgery: Surgery is Elective. Repair is typically deferred for 48–96 hours (or more) until the infant is hemodynamically stable, PPHN is controlled, and "honeymoon" period of low PVR has passed.
• Surgical Repair:
  • Defect Closure: Reduction of herniated contents and closure of the diaphragmatic defect (sutured primary repair or patch repair using synthetic material or autologous tissue).
  • Approach: Traditionally open laparotomy; minimally invasive (laparoscopic/thoracoscopic) repair is increasingly used in stable neonates or delayed presentations.

Monitoring

• Pulmonary Function: Long-term follow-up for reactive airway disease, chronic lung disease (CLD), and oxygen requirement.
• Cardiology: Repeat ECHO 6–12 months post-discharge and as needed to monitor for recurrent PPHN and right ventricular function.
• Neurodevelopmental: Regular assessment due to high risk of delays (e.g., Bayley Scales).

Treatment Algorithms

First-Line (Stabilization)

1. Immediate intubation and ventilatory support (Volume-targeted or pressure-regulated, low PIP $\le 25 \text{ cmH}_2\text{O}$).
2. NGT/OGT placement to suction.
3. Establish vascular access, initiate gentle fluid resuscitation/inotropes to maintain perfusion.
4. Delay surgery until PPHN is managed and patient is stable (Goal: $PaO_2/FiO_2 > 200$, OI < 25, $SaO_2$ 85–95%).

Second-Line (Refractory Respiratory Failure)

1. Initiation of $\text{iNO}$ (20 $\text{ppm}$).
2. High-Frequency Oscillatory Ventilation (HFOV) can be attempted, but caution is advised due to risk of barotrauma.
3. Optimization of sedation and pain control to reduce oxygen consumption.

Refractory Cases (Failure of Conventional and Advanced Therapies)

• ECMO (Extracorporeal Membrane Oxygenation): Indicated for infants failing to achieve stabilization criteria (e.g., OI > 40, $PaO_2/FiO_2 < 60$, severe pulmonary hypertension/cardiac failure).
  • Veno-arterial (VA-ECMO): Provides both respiratory and hemodynamic support.
  • Veno-venous (VV-ECMO): Primarily respiratory support.
• Surgical Repair During ECMO: Can be performed safely, but often deferred until weaning parameters are met.

---

Complications

Common

• Gastroesophageal Reflux Disease (GERD): Occurs in over 50% of patients due to anatomical distortion and surgical manipulation of the hiatus.
• Recurrence: Occurs in 10–20% of patch repairs, less frequently in primary suture repairs.
• Chronic Lung Disease (CLD): Persistent requirement for supplemental oxygen or ongoing respiratory symptoms.

Serious

• Persistent Pulmonary Hypertension of the Newborn (PPHN): Main cause of mortality.
• Pneumothorax: High risk, especially in the contralateral, "good" lung, often due to aggressive ventilation.
• Neurodevelopmental Delay: Due to hypoxemia, prematurity, or ECMO exposure (up to 50%).

Long-term

• Pulmonary morbidities (asthma-like symptoms, restrictive lung disease).
• Growth failure/failure to thrive.
• Hearing impairment (ototoxicity from medications or ECMO).
• Scoliosis and chest wall deformities.

---

Prognosis

Factors Affecting Outcome

• Prenatal Predictors (Severe Disease): O/E LHR $< 25\%$, total fetal lung volume low, liver herniation into the chest (Liver-Up position).
• Postnatal Predictors: Requirement for ECMO, lower Apgar scores, presence of associated major anomalies, early and severe PPHN presentation.
• Etiology: Isolated CDH has a better prognosis than syndromic CDH.

Survival

• Overall Survival: 70–80% in specialized centers.
• ECMO Patients: Survival rates vary highly, generally 50–60%.
• Liver-Down (less severe): Survival > 90%.
• Liver-Up (severe): Survival 50–60%.

Quality of Life

Long-term survivors typically have reduced exercise tolerance, chronic respiratory symptoms, and a higher reliance on specialized medical care. Neurodevelopmental surveillance is essential through school age.

---

Prevention

Primary

• Currently, no standard drug or intervention prevents the formation of CDH.

Secondary (Prenatal Intervention)

• Fetal Endoscopic Tracheal Occlusion (FETO): Reserved for fetuses with severe CDH ($\text{O/E LHR} < 25$ and Liver-Up).
  • Mechanism: Temporary balloon occlusion of the fetal trachea (1 week 26–30) induces fluid retention in the lungs, promoting lung growth (accelerated distal airway expansion).
  • Goal: Improve survival rates in the highest-risk group, though long-term pulmonary outcomes remain a concern.

Tertiary

• Aggressive post-surgical rehabilitation, respiratory support, and management of PPHN to prevent complications and optimize lung function.

---

Special Populations

Pediatric

• Follow-up: Required until young adulthood. Focus on nutritional support, growth parameters, development, hearing, and specialized pulmonary care.

Geriatric

• N/A (CDH is a neonatal condition, though late-presenting Morgagni hernias occur in older adults).

Pregnancy

• Prenatal Management: If severe CDH is diagnosed, mothers should be counseled and delivered at a tertiary care center with immediate access to neonatal surgery, ECMO, and specialized care. Delivery should optimally be planned at 39–40 weeks gestation unless contraindications exist.

Comorbidities

• Cardiac Defects: Require simultaneous cardiac management and stabilization before or after CDH repair, significantly increasing complexity and mortality risk.
• Chromosomal Syndromes: Prognosis is typically dictated by the underlying syndrome.

---

Clinical Pearls

Diagnostic

• Never attempt bag-mask ventilation in a suspected CDH infant; it is a life-threatening error due to massive gastric distension.
• A scaphoid abdomen in a neonate with respiratory distress is virtually pathognomonic for CDH.
• Listen carefully for bowel sounds in the chest, particularly in the axilla or back.

Treatment

• Timing of Surgery: Stabilize the lungs and heart before repair. CDH repair is an anatomical fix, not a physiological rescue. Premature surgery can destabilize PPHN.
• Pulmonary hypertension drives mortality. Therapy should be focused on preventing and treating PPHN aggressively (vasodilation, adequate oxygenation, maintaining systemic pressure).

Pitfalls

• Unrecognized contralateral pneumothorax (which can be masked by surrounding intestines or severe shunting).
• Over-ventilation: Using high pressures to achieve normal $\text{PaO}_2$ and $\text{PaCO}_2$ causes barotrauma and worsens vascular injury, pushing the patient toward ECMO. Favor permissive hypercapnia.

---

Recent Updates

Guidelines

• CDH Study Group (CDHSG) Guidelines: Emphasize the multidisciplinary approach, standardized reporting, and delayed surgical repair (48–96 hours or more) until pre-operative stabilization criteria are met ($PaO_2/FiO_2 > 200$).
• Increased use of Volume-Targeted Ventilation over pressure-controlled modes to minimize lung injury.

Evidence

• FETO Trials: Recent data supports FETO for severe isolated CDH, showing improved survival rates compared to standard care in selected high-risk populations, though risks associated with prematurity remain.
• Long-Term Outcomes: Growing evidence highlights the significant long-term neurodevelopmental and pulmonary morbidity, stressing the need for specialized long-term follow-up clinics ("CDH Clinic").

Controversies

• Optimal Timing of Repair: While delayed surgery is standard, the precise criteria for determining "optimal stability" remain debated, especially regarding patients requiring high vasopressor support.
• Role of Right-Sided CDH Management: Right-sided defects have a poorer prognosis due to potential liver injury and difficulty with surgical exposure; debate continues regarding specific ventilation strategies for this subset.

---

Key References

Guidelines

• Jobe AH. Fetal and neonatal pulmonary pathophysiology of congenital diaphragmatic hernia. Clin Perinatol. 2017;44(3):805–817.
• Congenital Diaphragmatic Hernia Study Group (CDHSG) consensus guidelines.

Studies

• Snoek KG, et al. Worldwide survival and practice variation in congenital diaphragmatic hernia. Semin Perinatol. 2019;43(7):450–458.
• Jani J, et al. Fetoscopic tracheal occlusion (FETO) for severe left-sided congenital diaphragmatic hernia: a systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2015;46(4):657–663.

---

Medical Disclaimer

This information is intended for educational purposes only and serves as a clinical reference. It is not a substitute for professional medical judgment, diagnosis, or treatment. Clinical decisions regarding the management of Congenital Diaphragmatic Hernia must be made by qualified healthcare professionals based on the specific clinical status of the patient, current evidence, and institutional protocols. Always consult with a specialist for advice regarding patient care.